about
Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remissionCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisAdult Acute Myeloid Leukemia Long-term Survivors.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Next generation MRD.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationNumber of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTClinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaBCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemiaDetection and Identification of Hematologic Malignancies and Solid Tumors by an Electrochemical Technique.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran.Precision medicine for acute myeloid leukemiaPre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Personalized therapy for acute myeloid leukemia.CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Minimal residual disease testing in hematologic malignancies and solid cancer.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.New approaches for the immunotherapy of acute myeloid leukemia.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaTechnical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing.Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell TransplantationMinimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
P2860
Q21245489-B5F2EC01-8457-439C-9DE0-5E7D261D08B7Q26863756-D05E54E0-C4B4-45CE-B272-6A1505ABC579Q28087291-97E9B2D2-7A29-4E74-905E-D962F40A92A1Q30234914-C08B2BD2-807C-4C4C-A790-A4B04D7BCD35Q33815986-D08EBCB4-C494-45CB-B7DC-AEDD78DE7943Q34202366-F180206F-C52E-4205-9672-E1F398888974Q34380489-30842D2E-8E64-4767-9A87-0D3444555B00Q34406955-86A191AF-5052-4186-9225-B70DF9130EEAQ34715598-C5835183-0A54-42DE-9395-1E1AAADCAC08Q34861985-414FA4F6-1FEE-4ACF-9ED0-B9E856831855Q34979564-E42D312B-B1D1-4F14-8B01-BAF24D0C4DB9Q35546759-AB231CDC-962D-4A78-AC32-AD29007DBC9CQ35582360-6BC4421F-9DDA-4D14-90AB-9AB472B5B870Q35604619-24FCB56C-0988-4F94-81C8-4A535723A2AEQ35663024-CB1BF675-3770-429E-BD9F-8D6492949334Q35999322-784A47DC-76A1-4EFF-97ED-D9B278CC48B2Q36157233-E35C1D10-DB99-47A7-8D79-0652CA4420C3Q36208652-586665B4-A59E-44B5-AF49-C2D4BCFE3427Q36561772-9F25CA95-C594-4939-99CF-0C1DABDE74F8Q36761201-AF3F4389-248B-4BB3-A8B4-0889BBD4C4ECQ36934758-E6AF5C01-4C89-4B35-8D1B-1EC522011994Q37072126-8DFA8EBE-EDAD-48D1-90B5-1DEBCF29BC35Q37141503-B5491E7A-F866-4ABD-B3D2-D77E83915852Q37432301-D9DB702A-48AD-4641-A3E3-4E6048E9A643Q38186870-8A6D3190-89A4-426B-8D99-1875F66E42A2Q38212956-2005737A-813A-49BB-97FF-DCF72C731E76Q38220970-5DBCB570-01CD-4644-BAEA-A949D4906FC5Q38240563-83BCE8C7-6A0C-4F22-892B-57BAC9235C77Q38482206-D24A6BB3-FB02-46E2-B66B-9C33B217E57DQ38755213-77DF1096-7361-4150-AEFB-6BC75C29DD87Q39132424-01BFF63C-40F8-443A-855A-338F11B5DE74Q40471975-0659D69F-5C92-46CA-A572-746A26D785BFQ41264435-DF09A728-CC90-42A7-A088-71C91AEA69C1Q41674738-630EEB7E-C87E-4A48-A8F0-20C2AFCD44D9Q42337304-538712B0-3F7E-424D-9A94-3EF9225BC130Q42559107-E538234F-DF63-4564-B649-E65D3D24D21CQ42711146-E2E80E3E-EB8A-4C76-B6FE-6651D6C91643Q43175202-0DE7C51E-890E-4C94-822B-8DA67A736B96Q44222759-EB7F83F3-E892-4CED-9EE9-22D03015216DQ45886072-518A8428-84C3-462D-A3A2-6C438CC95D04
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Minimal residual disease in acute myeloid leukaemia
@ast
Minimal residual disease in acute myeloid leukaemia
@en
Minimal residual disease in acute myeloid leukaemia
@nl
type
label
Minimal residual disease in acute myeloid leukaemia
@ast
Minimal residual disease in acute myeloid leukaemia
@en
Minimal residual disease in acute myeloid leukaemia
@nl
prefLabel
Minimal residual disease in acute myeloid leukaemia
@ast
Minimal residual disease in acute myeloid leukaemia
@en
Minimal residual disease in acute myeloid leukaemia
@nl
P2860
P1476
Minimal residual disease in acute myeloid leukaemia
@en
P2093
Judith E Karp
P2860
P304
P356
10.1038/NRCLINONC.2013.100
P407
P577
2013-06-25T00:00:00Z